Pharmacokinetics of mercaptopurine: plasma drug and red cell metabolite concentrations after an oral dose.

Abstract

Measurement of red cell 6-mercaptopurine (MP) derived 6-thioguanine nucleotide (TGN) and methylmercaptopurine metabolites (MeMPs) can be used to monitor therapy in children who are administered MP for childhood lymphoblastic leukemia. Red cell TGNs are not influenced by the time of blood sampling in relation to the last MP dose. The purpose of this study was to find out whether the same is true for the MeMPs. Plasma MP and red cell MP metabolite pharmacokinetics were studied in seven children immediately before and for 4 hours after a protocol standardized dose of MP. Duplicate blood samples were taken, one was processed immediately whereas one was left at an ambient temperature for 24 hours. The variation in TGN and MeMP metabolites over the 0- to 4-hour period (10 time points per child) was within the error of the assays used. The coefficients of variation for the TGNs ranged from 2.7% to 7% and for the MeMPs, 4% to 10.7%. There was no difference in the TGN and MeMP concentrations measured when the blood samples were left for 24 hours. If a child takes a MP tablet immediately before a clinic appointment, it has no major influence on MeMP measurements.

• Authors: J Welch, L Lennard, G C Morton, J S Lilleyman
• Journal: Therapeutic drug monitoring (Ther Drug Monit) Vol. 19 Issue 4 Pg. 382-5 (Aug 1997) ISSN: 0163-4356 [Print] United States
• PMID: 9263376 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antimetabolites, Antineoplastic
• Guanine Nucleotides
• Thionucleotides
• 6-thioguanylic acid
• 6-methylthiopurine
• Mercaptopurine

Topics

• Administration, Oral
• Antimetabolites, Antineoplastic (administration & dosage, metabolism, pharmacokinetics)
• Child
• Child, Preschool
• Erythrocytes (metabolism)
• Female
• Guanine Nucleotides (blood, metabolism)
• Humans
• Male
• Mercaptopurine (administration & dosage, analogs & derivatives, blood, metabolism, pharmacokinetics)
• Precursor Cell Lymphoblastic Leukemia-Lymphoma (drug therapy, metabolism)
• Thionucleotides (blood, metabolism)
• Time Factors